Comparative study of clonidine vs dexmedotomidine as an adjuvant to intrathecal hyperbaric bupivacaine for lower abdominal surgeries
Author(s): Leelavathi Bikumalla
Abstract:Background of the study: Spinal block is the technique of choice for surgeries in lower abdominal regions. Bupivacaine is defined as the commonly utilized local anesthetic. Several adjuvants have been utilized to enhance the standard of analgesia over the time of post- surgery. In this research, we utilized α2 –agonists such as clonidine and dexmedetomidine.
Objectives: The goal of the research analysis is to compare the consequences of dexmedetomidine as well as clonidine as adjuvants to intrathecal hyperbaric 0.5% bupivacaine concerning the sensory and motor onset time and duration of post operative analgesia for surgeries in lower abdominal region.
Methods: In this research, a total of 100 number of patients belonging to both sexes of ASA grade I as well as II were randomly allocated into two groups. Group BC injected with 0.5% hyperbaric bupivacaine along with 30µg of clonidine and Group BD each injected with 0.5% hyperbaric bupivacaine along with 5 µg of dexmedetomidine.
Data Analysis: Statistical data were depicted as mean±SD as well as the data was evaluated by SPSS software. This study utilizes two type of statistical analysis include Chi-square test as well as independent t-test for unpaired samples were used to find the significant value. Value of ‘P’ is low than (<0.05) was measured as implication value.
Results: Average sensory onset duration in Group BC was1.5 ±0.4 min whereas in Group BD was 1.3±0.5 min. Time for rescue analgesic in Group BC was 366±26.8 minutes in Group BC and Group BD was 398.8±32.5 which was statistically significant.
Conclusions: Dexmedetomidine as compared to clonidine with hyperbaric bupivacaine injected in subarachnoid space have a quicker initiation of sensory and motor block. In addition to, it lengthens the time period of analgesia.
Leelavathi Bikumalla. Comparative study of clonidine vs dexmedotomidine as an adjuvant to intrathecal hyperbaric bupivacaine for lower abdominal surgeries. Int J Adv Res Med 2022;4(1):182-185. DOI: 10.22271/27069567.2022.v4.i1c.370